OBJECTIVE: This study evaluated patient satisfaction with SoloSTAR® (sanofi-aventis), a prefilled insulin pen device for injection of insulin glargine or insulin glulisine. METHODS: This was a 6-8-week multicenter (n = 652), observational, prospective Pan-European and Canadian registry study in patients with diabetes mellitus (n = 6542) who recently switched to or started treatment with insulin glargine and/or insulin glulisine using SoloSTAR or were insulin naïve. At the baseline visit, patients were asked to evaluate their satisfaction with their previous device, if applicable. After 6-8 weeks of SoloSTAR use, patients were asked to rate their satisfaction. RESULTS: Overall, 6481 patients (mean age 54 years, 48.7% male, 72% type 2 diabetes) were analyzed in this study. Of these, 4995 (77.1%) patients had used insulin before the study and 1641 (32.9%) and 3395 (68.0%) patients had previously used prefilled and/or reusable pens, respectively. During the study, SoloSTAR was used to administer insulin glargine and/or insulin glulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). Most patients rated SoloSTAR as "excellent/good" for ease of use (97.9%), learning to use (98.3%), selecting the dose (97.6%), and reading the dose (95.1%). Most patients rated ease of use (88.4%) and injecting a dose (84.5%) with SoloSTAR as "much easier/easier" versus their previous pen. Overall, 98% planned to continue using SoloSTAR. No safety concerns were reported. CONCLUSION: This European and Canadian survey shows that SoloSTAR was well accepted in this large patient population. Most patients preferred SoloSTAR to their previous pen and planned to continue SoloSTAR use.
OBJECTIVE: This study evaluated patient satisfaction with SoloSTAR® (sanofi-aventis), a prefilled insulin pen device for injection of insulin glargine or insulinglulisine. METHODS: This was a 6-8-week multicenter (n = 652), observational, prospective Pan-European and Canadian registry study in patients with diabetes mellitus (n = 6542) who recently switched to or started treatment with insulinglargine and/or insulinglulisine using SoloSTAR or were insulin naïve. At the baseline visit, patients were asked to evaluate their satisfaction with their previous device, if applicable. After 6-8 weeks of SoloSTAR use, patients were asked to rate their satisfaction. RESULTS: Overall, 6481 patients (mean age 54 years, 48.7% male, 72% type 2 diabetes) were analyzed in this study. Of these, 4995 (77.1%) patients had used insulin before the study and 1641 (32.9%) and 3395 (68.0%) patients had previously used prefilled and/or reusable pens, respectively. During the study, SoloSTAR was used to administer insulinglargine and/or insulinglulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). Most patients rated SoloSTAR as "excellent/good" for ease of use (97.9%), learning to use (98.3%), selecting the dose (97.6%), and reading the dose (95.1%). Most patients rated ease of use (88.4%) and injecting a dose (84.5%) with SoloSTAR as "much easier/easier" versus their previous pen. Overall, 98% planned to continue using SoloSTAR. No safety concerns were reported. CONCLUSION: This European and Canadian survey shows that SoloSTAR was well accepted in this large patient population. Most patients preferred SoloSTAR to their previous pen and planned to continue SoloSTAR use.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: J Clin Epidemiol Date: 2008-04 Impact factor: 6.437
Authors: Manjiri D Pawaskar; Fabian T Camacho; Roger T Anderson; David Cobden; Ashish V Joshi; Rajesh Balkrishnan Journal: Clin Ther Date: 2007-06 Impact factor: 3.393
Authors: Małgorzata Masierek; Katarzyna Nabrdalik; Hanna Kwiendacz; Tomasz Sawczyn; Janusz Gumprecht Journal: Int J Environ Res Public Health Date: 2020-10-19 Impact factor: 3.390